D. Hanahan and R. Weinberg, The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000.
DOI : 10.1016/S0092-8674(00)81683-9

F. Balkwill and K. Charles, Smoldering and polarized inflammation in the initiation and promotion of malignant disease, Cancer Cell, vol.7, issue.3, pp.211-218, 2005.
DOI : 10.1016/j.ccr.2005.02.013

W. Lin and K. M. , A cytokine-mediated link between innate immunity, inflammation, and cancer, Journal of Clinical Investigation, vol.117, issue.5, pp.1175-83, 2007.
DOI : 10.1172/JCI31537

M. Karin, F. Greten, and . Nf-kappab, NF-??B: linking inflammation and immunity to cancer development and progression, Nature Reviews Immunology, vol.100, issue.10, pp.749-59, 2005.
DOI : 10.1038/nri1703

M. Nicolau, R. Tibshirani, A. Borresen-dale, and S. Jeffrey, Disease-specific genomic analysis: identifying the signature of pathologic biology, Bioinformatics, vol.23, issue.8, pp.957-65, 2007.
DOI : 10.1093/bioinformatics/btm033

E. Segal, N. Friedman, N. Kaminski, A. Regev, and D. Koller, From signatures to models: understanding cancer using microarrays, Nature Genetics, vol.57, issue.6s, pp.38-45, 2005.
DOI : 10.1073/pnas.0400782101

R. Lucito and . Representational, Representational Oligonucleotide Microarray Analysis: A High-Resolution Method to Detect Genome Copy Number Variation, Genome Research, vol.13, issue.10, pp.2291-305, 2003.
DOI : 10.1101/gr.1349003

B. Weir, Characterizing the cancer genome in lung adenocarcinoma, Nature, vol.15, issue.7171, pp.893-901, 2007.
DOI : 10.1038/nature06358

H. Wang, H. Han, S. Mousses, and V. Hoff, Targeting Loss-of-Function Mutations in Tumor-Suppressor Genes as a Strategy for Development of Cancer Therapeutic Agents, Seminars in Oncology, vol.33, issue.4
DOI : 10.1053/j.seminoncol.2006.04.013

Y. Izumi, L. Xu, E. Di-tomaso, D. Fukumura, and R. Jain, Tumour biology: Herceptin acts as an anti-angiogenic cocktail, Nature, vol.94, issue.6878, pp.279-80, 2002.
DOI : 10.1038/416279b

B. Druker and . Sti571, STI571 (Gleevec???) as a paradigm for cancer therapy, Trends in Molecular Medicine, vol.8, issue.4, pp.14-22, 2002.
DOI : 10.1016/S1471-4914(02)02305-5

D. Basseres and A. Baldwin, Nuclear factor-??B and inhibitor of ??B kinase pathways in oncogenic initiation and progression, Oncogene, vol.107, issue.51, pp.6817-6847, 2006.
DOI : 10.1677/erc.1.00977

P. Jost and J. Ruland, Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications, Blood, vol.109, pp.2700-2707, 2007.

D. Cilloni, G. Martinelli, F. Messa, M. Baccarani, and G. Saglio, Nuclear factor ??B as a target for new drug development in myeloid malignancies, Haematologica, vol.92, issue.9, pp.1224-1233
DOI : 10.3324/haematol.11199

J. Dutta, Y. Fan, N. Gupta, G. Fan, and C. Gelinas, Current insights into the regulation of programmed cell death by NF-??B, Oncogene, vol.13, issue.51, pp.6800-6816, 2006.
DOI : 10.1038/nature02273

J. Luo, H. Kamata, and K. M. , The Anti-Death Machinery in IKK/NF-??B Signaling, Journal of Clinical Immunology, vol.6, issue.6, pp.541-50, 2005.
DOI : 10.1007/s10875-005-8217-6

E. Burstein, C. Duckett, . Dying, and . Nf-kappab, Dying for NF-??B? Control of cell death by transcriptional regulation of the apoptotic machinery, Current Opinion in Cell Biology, vol.15, issue.6, pp.732-739, 2003.
DOI : 10.1016/j.ceb.2003.10.005

M. Karin, Nuclear factor-??B in cancer development and progression, Nature, vol.12, issue.7092, pp.431-437, 2006.
DOI : 10.1038/nature04870

T. Lawrence, M. Bebien, G. Liu, V. Nizet, and K. M. , IKK?? limits macrophage NF-??B activation and contributes to the resolution of inflammation, Nature, vol.259, issue.7037, pp.1138-1181, 2005.
DOI : 10.1126/science.1098387

E. Pikarsky and . Nf-, NF-??B functions as a tumour promoter in inflammation-associated cancer, Nature, vol.2, issue.7007, pp.461-467, 2004.
DOI : 10.1006/scbi.2000.0360

J. Luo, H. Kamata, M. Karin, and . Ikk, IKK/NF-??B signaling: balancing life and death - a new approach to cancer therapy, Journal of Clinical Investigation, vol.115, issue.10, pp.2625-2657, 2005.
DOI : 10.1172/JCI26322

C. Nakanishi and T. M. , Nuclear factor-??B inhibitors as sensitizers to anticancer drugs, Nature Reviews Cancer, vol.21, issue.4, pp.297-309, 2005.
DOI : 10.1084/jem.183.4.1829

S. Ghosh, M. May, E. Kopp, and B. Nf-kappa, NF-??B AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses, Annual Review of Immunology, vol.16, issue.1, pp.225-60, 1998.
DOI : 10.1146/annurev.immunol.16.1.225

S. Ghosh and K. M. , Missing Pieces in the NF-??B Puzzle, Cell, vol.109, issue.2, pp.81-96, 2002.
DOI : 10.1016/S0092-8674(02)00703-1

V. Baud and K. M. , Signal transduction by tumor necrosis factor and its relatives, Trends in Cell Biology, vol.11, issue.9, pp.372-379, 2001.
DOI : 10.1016/S0962-8924(01)02064-5

G. Bonizzi and K. M. , The two NF-??B activation pathways and their role in innate and adaptive immunity, Trends in Immunology, vol.25, issue.6, pp.280-288, 2004.
DOI : 10.1016/j.it.2004.03.008

E. Derudder and . Relb, RelB/p50 Dimers Are Differentially Regulated by Tumor Necrosis Factor-?? and Lymphotoxin-?? Receptor Activation: CRITICAL ROLES FOR p100, Journal of Biological Chemistry, vol.278, issue.26, pp.23278-23284, 2003.
DOI : 10.1074/jbc.M300106200

G. Xiao and E. Harhaj, NF-??B-Inducing Kinase Regulates the Processing of NF-??B2 p100, Molecular Cell, vol.7, issue.2, pp.401-409, 2001.
DOI : 10.1016/S1097-2765(01)00187-3

E. Claudio, K. Brown, S. Park, and H. Wang, BAFF-induced NEMO-independent processing of NF-??B2 in maturing B cells, Nature Immunology, vol.3, issue.10, pp.958-65, 2002.
DOI : 10.1038/ni842

J. Pomerantz and D. Baltimore, Two Pathways to NF-??B, Molecular Cell, vol.10, issue.4, pp.693-698, 2002.
DOI : 10.1016/S1097-2765(02)00697-4

URL : http://doi.org/10.1016/s1097-2765(02)00697-4

R. Kyle, S. Rajkumar, and . Multiple-myeloma, Multiple Myeloma, New England Journal of Medicine, vol.351, issue.18, pp.1860-73, 2004.
DOI : 10.1056/NEJMra041875

URL : https://hal.archives-ouvertes.fr/hal-00557757

M. Engelhardt and R. Mertelsmann, 160 years of multiple myeloma: Progress and challenges, European Journal of Cancer, vol.42, issue.11, pp.1507-1516, 2006.
DOI : 10.1016/j.ejca.2006.05.003

U. Denz, P. Haas, R. Wasch, and H. Einsele, State of the art therapy in multiple myeloma and future perspectives, European Journal of Cancer, vol.42, issue.11, pp.1591-600, 2006.
DOI : 10.1016/j.ejca.2005.11.040

K. Podar, P. Richardson, T. Hideshima, D. Chauhan, and K. Anderson, The malignant clone and the bone-marrow environment, Best Practice & Research Clinical Haematology, vol.20, issue.4, pp.597-612, 2007.
DOI : 10.1016/j.beha.2007.08.002

. Ni, Analysis of expression of nuclear factor kappaB (NF-kappaB) in multiple myeloma: downregulation of NF-kappaB induces apoptosis, British Journal of Haematology, vol.44, issue.2, pp.279-86, 2001.
DOI : 10.1006/scbi.1997.0058

T. Hideshima and . Nf-kappa, NF-??B as a Therapeutic Target in Multiple Myeloma, Journal of Biological Chemistry, vol.277, issue.19, pp.16639-16686, 2002.
DOI : 10.1074/jbc.M200360200

A. Bharti, N. Donato, S. Singh, B. Aggarwal, and . Curcumin, Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikappa Balpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis, Blood, vol.101, issue.3, pp.1053-62, 2003.
DOI : 10.1182/blood-2002-05-1320

T. Hideshima and . Mln120b, MLN120B, a Novel I??B Kinase ?? Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo, Clinical Cancer Research, vol.12, issue.19, pp.5887-94, 2006.
DOI : 10.1158/1078-0432.CCR-05-2501

M. Jourdan and . Targeting, B pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth, British Journal of Haematology, vol.83, issue.2, pp.160-168, 2007.
DOI : 10.1111/j.1365-2141.2007.06629.x

URL : https://hal.archives-ouvertes.fr/inserm-00160647

. Sanda, Growth Inhibition of Multiple Myeloma Cells by a Novel I??B Kinase Inhibitor, Clinical Cancer Research, vol.11, issue.5, pp.1974-82, 2005.
DOI : 10.1158/1078-0432.CCR-04-1936

R. Feng and . Sdx-, SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-??B activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth, Blood, vol.109, issue.5, pp.2130-2138, 2007.
DOI : 10.1182/blood-2006-07-027458

. Dai, Interruption of the NF-kappaB pathway by Bay 11 7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells ?

. Mitsiades, Biologic sequelae of nuclear factor-kappa B blockade in multiple myeloma: therapeutic applications, Blood, vol.99, issue.11, pp.4079-86, 2002.
DOI : 10.1182/blood.V99.11.4079

D. Chauhan, Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B, Blood, vol.87, pp.1104-1116, 1996.

T. Landowski, N. Olashaw, D. Agrawal, and W. Dalton, Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-??B (RelB/p50) in myeloma cells, Oncogene, vol.22, issue.16, pp.2417-2438, 2003.
DOI : 10.1038/sj.onc.1206315

M. Hecht, V. Metzler, I. Sack, K. Kaiser, M. Sezer et al., Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA), Experimental Cell Research, vol.314, issue.5, pp.1082-93, 2008.
DOI : 10.1016/j.yexcr.2007.10.021

T. Hideshima, K. Podar, D. Chauhan, and K. Anderson, Cytokines and signal transduction, Best Practice & Research Clinical Haematology, vol.18, issue.4, pp.509-533, 2005.
DOI : 10.1016/j.beha.2005.01.003

R. Niesvizky, The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma, British Journal of Haematology, vol.108, issue.1, 2008.
DOI : 10.1111/j.1365-2141.2008.07303.x

P. Richardson, C. Mitsiades, R. Schlossman, and N. Munshi, New Drugs for Myeloma, The Oncologist, vol.12, issue.6, pp.664-89, 2007.
DOI : 10.1634/theoncologist.12-6-664

T. Hideshima, D. Chauhan, R. Schlossman, P. Richardson, and K. Anderson, The role of tumor necrosis factor ?? in the pathophysiology of human multiple myeloma: therapeutic applications, Oncogene, vol.20, issue.33, pp.4519-4546, 2001.
DOI : 10.1038/sj.onc.1204623

. Hideshima, The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells, Cancer Res, vol.61, pp.3071-3077, 2001.

G. Mulligan and . Gene, Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib, Blood, vol.109, issue.8, pp.3177-88, 2007.
DOI : 10.1182/blood-2006-09-044974

M. Hussein, Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma, British Journal of Haematology, vol.19, issue.4, pp.470-476, 2004.
DOI : 10.1056/NEJM199811053391901

J. Keifer, D. Guttridge, and B. Ashburner, Inhibition of NF-??B Activity by Thalidomide through Suppression of I??B Kinase Activity, Journal of Biological Chemistry, vol.276, issue.25, pp.22382-22389, 2001.
DOI : 10.1074/jbc.M100938200

. Annunziata, Frequent Engagement of the Classical and Alternative NF-??B Pathways by Diverse Genetic Abnormalities in Multiple Myeloma, Cancer Cell, vol.12, issue.2, pp.115-145, 2007.
DOI : 10.1016/j.ccr.2007.07.004

J. Keats, Promiscuous Mutations Activate the Noncanonical NF-??B Pathway in Multiple Myeloma, Cancer Cell, vol.12, issue.2, pp.131-175, 2007.
DOI : 10.1016/j.ccr.2007.07.003

G. Liao, M. Zhang, and E. Harhaj, Regulation of the NF-??B-inducing Kinase by Tumor Necrosis Factor Receptor-associated Factor 3-induced Degradation, Journal of Biological Chemistry, vol.279, issue.25, pp.26243-50, 2004.
DOI : 10.1074/jbc.M403286200

J. He, S. Saha, J. Kang, B. Zarnegar, and G. Cheng, Specificity of TRAF3 in Its Negative Regulation of the Noncanonical NF-??B Pathway, Journal of Biological Chemistry, vol.282, issue.6, pp.3688-94, 2007.
DOI : 10.1074/jbc.M610271200

S. Vallabhapurapu and . Traf2, TRAF3 carry out non-redundant and complementary functions in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling, Nat Immunol, 2008.

J. Vince, IAP Antagonists Target cIAP1 to Induce TNF??-Dependent Apoptosis, Cell, vol.131, issue.4, pp.682-93, 2007.
DOI : 10.1016/j.cell.2007.10.037

U. Karrer, A. Althage, B. Odermatt, and H. Hengartner, Immunodeficiency of alymphoplasia mice (aly/aly)in vivo: structural defect of secondary lymphoid organs and functional B cell defect, European Journal of Immunology, vol.3, issue.10, pp.2799-807, 2000.
DOI : 10.1002/1521-4141(200010)30:10<2799::AID-IMMU2799>3.0.CO;2-2

. Yamada, Abnormal Immune Function of Hemopoietic Cells from Alymphoplasia (aly) Mice, a Natural Strain with Mutant NF-??B-Inducing Kinase, The Journal of Immunology, vol.165, issue.2, pp.804-816, 2000.
DOI : 10.4049/jimmunol.165.2.804

Y. Sasaki, S. Casola, J. Kutok, and K. Rajewsky, TNF Family Member B Cell-Activating Factor (BAFF) Receptor-Dependent and -Independent Roles for BAFF in B Cell Physiology, The Journal of Immunology, vol.173, issue.4, pp.2245-52, 2004.
DOI : 10.4049/jimmunol.173.4.2245

S. Shulga-morskaya, B Cell-Activating Factor Belonging to the TNF Family Acts through Separate Receptors to Support B Cell Survival and T Cell-Independent Antibody Formation, The Journal of Immunology, vol.173, issue.4, pp.2331-2372, 2004.
DOI : 10.4049/jimmunol.173.4.2331

S. Gardam, F. Sierro, A. Basten, and F. Mackay, TRAF2 and TRAF3 Signal Adapters Act Cooperatively to Control the Maturation and Survival Signals Delivered to B Cells by the BAFF Receptor, Immunity, vol.28, issue.3, pp.391-401, 2008.
DOI : 10.1016/j.immuni.2008.01.009

N. Malinin, M. Boldin, and A. Kovalenko, MAP3K-related kinase involved in NF-KB induction by TNF, CD95 and IL-1, Nature, vol.385, issue.6616, pp.540-544, 1997.
DOI : 10.1038/385540a0

P. Ramakrishnan and W. Wang, Receptor-Specific Signaling for Both the Alternative and the Canonical NF-??B Activation Pathways by NF-??B-Inducing Kinase, Immunity, vol.21, issue.4, pp.477-89, 2004.
DOI : 10.1016/j.immuni.2004.08.009

C. Wang, M. Mayo, R. Korneluk, D. Goeddel, A. Baldwin et al., NF-B Antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to Suppress Caspase-8 Activation, Science, vol.281, issue.5383, pp.1680-1683, 1998.
DOI : 10.1126/science.281.5383.1680

D. Vaux, J. Silke, and . Iaps, IAPs, RINGs and ubiquitylation, Nature Reviews Molecular Cell Biology, vol.416, issue.4, pp.287-97, 2005.
DOI : 10.1038/nrm1621

A. Hunter and E. Lacasse, The inhibitors of apoptosis (IAPs) as cancer targets, Apoptosis, vol.279, issue.46, pp.1543-68, 2007.
DOI : 10.1007/s10495-007-0087-3

H. Shu, M. Takeuchi, and D. Goeddel, The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex, Proceedings of the National Academy of Sciences, vol.93, issue.24
DOI : 10.1073/pnas.93.24.13973

M. Rothe, M. Pan, W. Henzel, and T. Ayres, The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins, Cell, vol.83, issue.7, pp.1243-52, 1995.
DOI : 10.1016/0092-8674(95)90149-3

M. Rothe, S. Wong, and W. Henzel, A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor, Cell, vol.78, issue.4, pp.681-92, 1994.
DOI : 10.1016/0092-8674(94)90532-0

Y. Yang, S. Fang, J. Jensen, and A. Weissman, Ashwell JD Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli

X. Li and Y. Yang, TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2, Nature, vol.180, issue.6878, pp.345-352, 2002.
DOI : 10.1038/416345a

. Matsuzawa, Essential Cytoplasmic Translocation of a Cytokine Receptor-Assembled Signaling Complex, Science, vol.321, issue.5889, pp.663-671, 2008.
DOI : 10.1126/science.1157340

D. Conte, Inhibitor of Apoptosis Protein cIAP2 Is Essential for Lipopolysaccharide-Induced Macrophage Survival, Molecular and Cellular Biology, vol.26, issue.2, pp.699-708, 2006.
DOI : 10.1128/MCB.26.2.699-708.2006

C. Du, M. Fang, Y. Li, L. Li, X. Wang et al., Smac, a Mitochondrial Protein that Promotes Cytochrome c???Dependent Caspase Activation by Eliminating IAP Inhibition, Cell, vol.102, issue.1, pp.33-42, 2000.
DOI : 10.1016/S0092-8674(00)00008-8

D. Chauhan and . Smac, Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM), Blood, vol.109, issue.3, pp.1220-1227, 2007.
DOI : 10.1182/blood-2006-04-015149

L. Li, A Small Molecule Smac Mimic Potentiates TRAIL- and TNF??-Mediated Cell Death, Science, vol.305, issue.5689, pp.1471-1475, 2004.
DOI : 10.1126/science.1098231

R. Davis and L. Staudt, Molecular diagnosis of lymphoid malignancies by gene expression profiling, Current Opinion in Hematology, vol.9, issue.4, pp.333-341, 2002.
DOI : 10.1097/00062752-200207000-00011

A. Keutgens, I. Robert, and P. Viatour, Deregulated NF-??B activity in haematological malignancies, Biochemical Pharmacology, vol.72, issue.9, pp.1069-80, 2006.
DOI : 10.1016/j.bcp.2006.06.011

M. Karin, Y. Yamamoto, and Q. Wang, The IKK NF-??B system: a treasure trove for drug development, Nature Reviews Drug Discovery, vol.3, issue.1, pp.17-26, 2004.
DOI : 10.1038/nrd1279

F. Greten and . Nf-kappab, NF-??B Is a Negative Regulator of IL-1?? Secretion as Revealed by Genetic and Pharmacological Inhibition of IKK??, Cell, vol.130, issue.5, pp.918-949, 2007.
DOI : 10.1016/j.cell.2007.07.009